นิตยสาร สสวท. ฉบับที่ 235

36 นิตยสาร สสวท. ¤ÇÒÁ¨ÃÔ§áŌǿ‡Ò·ÐÅÒÂâ¨Ã໚¹¾×ª·Õ èÊíÒ¤Ñã¹Ç§¡ÒÃᾷἹ¨Õ¹ áÅÐᾷἹä·ÂÁÒ¹Ò¹áÅŒÇ à¹× èͧ´ŒÇ¿‡Ò·ÐÅÒÂâ¨ÃÁÕÄ·¸Ô ìàÂç¹ ¨Ö§¹ÔÂÁ ¹íÒÁÒ㪌໚¹ÂÒŴ䢌 㪌´Ñº¸ÒµØä¿·Õ èÊÙ§¢Ö é¹ã¹Ã‹Ò§¡Ò ઋ¹ ¡ÒÃŴ䢌 áÅÐ䴌ÃѺ ¡ÒúÃèØÍÂÙ ‹ã¹ºÑªÕÂÒËÅÑ¡áˋ§ªÒµÔµÑ é§áµ‹ ¾.È. 2542 (ºÑªÕÂÒÊÁعä¾Ã) «Öè§ÁÕ¢ŒÍº‹§ãªŒ ¤×Í á¡Œä¢Œ à¨çº¤Í ÃÑ¡ÉÒÍÒ¡Ò÷ŒÍ§àÊÕÂäÁ‹µÔ´àª×éÍ ¡ÒÃÈÖ¡ÉÒ·Ò§àÀÊѪÇÔ·ÂÒ¾ºÇ‹ÒÊÒà Andrographolide áÅР͹ؾѹ¸Ø ¢Í§ÊÒà (14-deoxy-11,12-didehydroandrographolide) ÊÒÁÒö Å´ÍÒ¡ÒÃ䢌 Å´ÍÒ¡ÒÃà¨çº»Ç´ áÅСÒÃÍÑ¡àʺ¢Í§Ë¹Ù·Õ è㪌㹡Ò÷´Åͧ䴌 (Suebsasana, Pongnaratorn, Sattayasai, Arkaravichien, Tiamkao & Aromdee, 2009) ª‹Ç¡ÃÐµØ Œ¹ÃкºÀÙÁÔ¤Ø ŒÁ¡Ñ¹ã¹¡Ò÷´Åͧ¢Í§Ë¹Ù·Õ èµÔ´àª× éÍ áº¤·ÕàÃÕ â´Âª‹ÇÂãˌÁÕ¡ÒÃËÅÑ è§ IgG, IgA Antibody, Interferon- γ (IFN- γ ) áÅÐ interleukin-2 (IL-2) «Ö è§áÊ´§ãˌàËç¹Ç‹Ò¿‡Ò·ÐÅÒÂâ¨ÃÊÒÁÒö ª‹ÇµŒÒ¹¡ÒõԴàª×éͧ͢¨ØŪվ·Õ衋ÍâäÀÒÂã¹à«Åŏ䴌 (Xu, 2009) ¨Ò¡¤ÇÒÁà¡Õ èÂÇà¹× èͧ¢Í§¤Ø³ÊÁºÑµÔ¢Í§¿‡Ò·ÐÅÒÂâ¨Ã áÅÐÊÒà ÍÍ¡Ä·¸Ô ìËÅÑ¡ Andrographolide µ‹ÍÍÒ¡ÒÃ·Õ è¤ÅŒÒ¤ÅÖ§¡Ñºâäâ¤ÇÔ´ - 19 ¿‡Ò·ÐÅÒÂâ¨Ã¨Ö§à»š¹ÊÁعä¾Ã·Õ èÁÕ¡ÒÃãˌ¤ÇÒÁʹã¨ã¹¡ÒùíÒÁÒ·´Êͺ ¡ÒÃÍÍ¡Ä·¸Ô 쵋Íàª× éÍäÇÃÑÊ SARS-CoV-2 ¹Í¡¨Ò¡¹Õ é Âѧ¾ºÇ‹ÒàÁ× èÍÁÕ¡Òà ·´Åͧâ´Â㪌à«ÅŏàÂ× èͺػʹ (Human Lung Epithelial Cells) Calu-3 cells ·Õè¶Ù¡·íÒãˌµÔ´àª×éÍ SARS-CoV-2 ¾ºÇ‹Ò ÊÒÃÊ¡Ñ´¨Ò¡¿‡Ò·ÐÅÒÂâ¨Ã·ÕèÊ¡Ñ´´ŒÇ àÍ·Ò¹ÍÅ áÅÐÊÒà Andrographolide ÊÒÁÒ Ã¶ÂÑ ºÂÑé §¡ÒÃµÔ ´ à ª×é Íä ´Œ Í‹ Ò §ÁÕ ¹ÑÂÂÐÊíÒ¤Ñ â´ÂÁÕ¤‹Ò IC50 (¤ÇÒÁࢌÁ¢Œ¹ ¢Í§ÊÒÃ·Õ èÊÒÁÒöÂѺÂÑ é§àª× éÍ䴌 50%) ¢Í§ÊÒÃÊ¡Ñ´¿‡Ò·ÐÅÒÂâ¨Ã·Õ è 9.54 µ g/mL áÅТͧ andrographolide ·Õ è 1.68 µ M ¹Í¡¨Ò¡¹Õ é Âѧ¾ºÇ‹ÒàÁ× èÍËÒ»ÃÔÁÒ³ äÇÃÑÊâ´Â¡ÒùѺ¨íҹǹ¡ÒÃà¡Ô´¾ÅѤ (Plaque Assay) ¿‡Ò·ÐÅÒÂâ¨Ã áÅÐÊÒÃÍÍ¡Ä·¸Ô ìÊÒÁÒöŴ¨íҹǹ¢Í§¾ÅѤ·Õèà¡Ô´¨Ò¡à«Åŏ·ÕèµÒ¨ҡ ¡ÒõԴàª×éÍŧ䴌·Õè IC50 µè íÒ (Sa-Ngiamsuntorn et al., 2021) ·Õ èÁÒ: Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component Andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives â´Â»¡µÔáŌÇàª× éÍäÇÃÑʨÐà¾Ô èÁ¨íҹǹ䴌¨ÐµŒÍ§ãªŒà«Åŏ¢Í§ Host ª‹ÇÂÊÌҧäÇÃÑʵÑÇãËÁ‹ «Ö è§ Spike (S) Glycoprotein ¢Í§äÇÃÑÊ SARS-CoV-2 ¨Ð¨Ñº¡Ñº ACE2 receptor º¹à«Åŏ¢Í§Á¹Øɏ ·íÒãˌà¡Ô´¡ÒÃËÅÍÁÃÇÁ à»Å×Í¡ËØ ŒÁäÇÃÑʡѺàÂ× èÍËØ ŒÁà«Åŏ¢Í§ Host áŌǻŋÍ RNA ¢Í§äÇÃÑÊࢌÒä» ã¹à«Åŏà¾× èͨíÒÅͧµÑÇàͧ (Replication) à¡Ô´¡ÒÃà¾Ô èÁ¨íҹǹäÇÃÑÊ ÁÕ¡ÒÃÈÖ¡ÉÒ ¾ºÇ‹ÒÊÒà Andrographolide ¹Õ éÊÒÁÒö¨ÐࢌÒዧ¨Ñº¡Ñº ACE2 Receptor áÅÐ M Protease ¢Í§àª× éÍäÇÃÑÊ«Ö è§ÁÕº·ºÒ·ÊíҤѢͧ¡ÒÃà¾Ô èÁ¨íҹǹáÅРẋ§µÑǢͧäÇÃÑÊ ·íÒãˌ Andrographolide ÊÒÁÒö»‡Í§¡Ñ¹äÇÃÑÊࢌÒÊÙ ‹à«Åŏ ÃÇÁ¶Ö§Å´¡ÒÃẋ§µÑǢͧà«ÅŏäÇÃÑÊ䴌 (Yan, Shen, Cao, Zhang, Wang & Cheng, 2020) ¡ÒÃÈÖ¡ÉÒʋǹãˋ¹Ñ 鹨Ð໚¹¡ÒÃÈÖ¡ÉÒã¹¢Ñ é¹¡‹Í¹¡ÒÃÈÖ¡ÉÒ·Ò§ ¤ÅÔ¹Ô¡ (Preclinical Phase) ÍÒ¨¨Ð´ŒÇÂ໚¹âäµÔ´àª× éÍÍغѵÔãËÁ‹¨Ö§ÁÕàÇÅÒ ÈÖ¡ÉÒ¤‹Í¹¢ŒÒ§¹ŒÍ ºÇ¡¡Ñº¨íҹǹà¤Ê·Õ èࢌÒÃѺ¡ÒÃÈÖ¡ÉÒäÁ‹ÁÒ¡ Í‹ҧäáçµÒÁ »ÃÐà·Èä·Â䴌ÁÕ¡ÒÃÈÖ¡ÉÒ¹íÒËͧâ´Â¡ÃÁ¡ÒÃᾷἹä·ÂáÅСÒÃᾷ ·Ò§àÅ×͡ËÇÁ¡Ñºâç¾ÂÒºÒÅÊÁطûÃÒ¡Òà ¡ÃÁÇÔ·ÂÒÈÒʵÏ¡ÒÃᾷáÅРͧ¤¡ÒÃàÀÊѪ¡ÃÃÁ à¡çº¢ŒÍÁÙÅÍÒÊÒÊÁѤü٠Œ»†ÇÂâ¤ÇÔ´-19 ÃдѺ¤ÇÒÁÃعáç ¹ŒÍ ¨íҹǹ 6 ¤¹ â´Â㪌ÂÒ¿‡Ò·ÐÅÒÂâ¨Ã·Õ èÁÕÊÒà Andrographolide ¢¹Ò´ 20 ÁÔÅÅÔ¡ÃÑÁµ‹Í᤻«ÙŠËÇÁ¡Ñº¡ÒÃÃÑ¡ÉÒµÒÁ»¡µÔ ¾ºÇ‹ÒÊÒÁÒöŴ ¤ÇÒÁÃعáç¢Í§ÍÒ¡ÒÃËÇÁ·Õ è»ÃÒ¡¯Í‹ҧÁÕ¹ÑÂÂÐÊíÒ¤Ñ·Ò§Ê¶ÔµÔ àª‹¹ ¡ÒÃäÍ à¨çº¤Í »ÃÔÁÒ³àÊÁËÐ ¡ÒûǴÈÕÃÉÐ áÅÐäÁ‹¾ºÍÒ¡ÒÃäÁ‹¾Ö§»ÃÐʧ¤ ¹Í¡¨Ò¡¹Õ é ¾ºÇ‹Ò¼Ù Œ»†Ç 3 ÃÒ µÃǨäÁ‹¾ºàª× éÍã¹Çѹ·Õ è 5 ËÅѧ¨Ò¡ä´ŒÃѺÂÒ (¡ÃÁ¡ÒÃᾷἹä·ÂáÅСÒÃᾷ·Ò§àÅ×Í¡ ¡ÃзÃǧÊÒ¸ÒóÊØ¢, 2019) «Ö 觼šÒÃÈÖ¡ÉÒ¹Õ é·íÒãˌàËç¹Ç‹Ò¿‡Ò·ÐÅÒÂâ¨Ããˌ¼Åã¹·ÔÈ·Ò§·Õ è´Õµ‹Í¡ÒÃÃÑ¡ÉÒ âäâ¤ÇÔ´-19 ᵋàÁ× èÍäÁ‹¹Ò¹ÁÒ¹Õ é ¨Ò¡Ê¶Ò¹¡Òó¡ÒÃÃкҴ໚¹¡ÅØ ‹Á¡ŒÍ¹ ¢¹Ò´ãˋã¹àÃ×͹¨íÒ¡Ãا෾ÁËÒ¹¤Ã ¡ÃÁ¡ÒÃᾷἹä·ÂáÅÐ ¡ÒÃᾷ·Ò§àÅ×Í¡áÅÐà¤Ã×Í¢‹Ò 䴌¨Ñ´Ê‹§ÂÒÊÁعä¾Ãä»ãˌ¼ÙŒµÔ´àª× éÍ áÅР䴌µÔ´µÒÁ¡ÒÃ㪌ÂÒ¿‡Ò·ÐÅÒÂâ¨ÃẺº´¼§ ¢¹Ò´ 400 ÁÔÅÅÔ¡ÃÑÁµ‹Í ᤻«ÙÅ áÅСÃЪÒ¢ÒÇẺÊÒÃÊ¡Ñ´ ¢¹Ò´ 100 ÁÔÅÅÔ¡ÃÑÁ à»ÃÕºà·Õº¡Ñº ÂÒá¼¹»˜¨¨ØºÑ¹ Favipiravir 㹡ÅØ ‹Á¤¹·Õ èäÁ‹ÁÕÍÒ¡Ò÷ҧ¤ÅÕ¹Ô¡ ¨íҹǹ 120 ÃÒ ¨Ò¡¹Ñ é¹ÁÕ¡ÒõԴµÒÁ¼Å¡ÒáíҨѴàª× éÍ SARS-CoV-2 â´Â¡Òà à¡çºµÑÇÍ‹ҧ Nasopharyngeal Swab Çѹànj¹ 2 Çѹ ʋ§µÃǨ´ŒÇÂà·¤¹Ô¤ RT-PCR ¨Ò¡¼Å¡ÒÃÈÖ¡ÉÒ¾ºÇ‹Ò ¨íҹǹÇѹ·Õ èà¡çºµÑÇÍ‹ҧ¨¹ä»¶Ö§Çѹ·Õ è äÁ‹¾ºàª× éÍ ¿‡Ò·ÐÅÒÂâ¨ÃẺº´¼§ ÊÒÃÊ¡Ñ´¡ÃЪÒ¢ÒÇáÅп‡Ò·ÐÅÒÂâ¨Ã ËÇÁ¡Ñº¡ÃЪÒ¢ÒÇ ãªŒàÇÅÒ·Ñ é§ÊÔ é¹ 8 Çѹ ʋǹÂÒ Favipiravir 㪌àÇÅÒ 12 Çѹ ¨Ò¡¼Å¡ÒÃÃÑ¡ÉÒ¾ºÇ‹ÒÊÒÁÒöŴÃÐÂÐàÇÅÒ¡ÒÃÃÑ¡ÉÒ áÅÐÃÐÂÐàÇÅÒ ¡ÒâѺàª× éÍ (Viral Shedding) 䴌´Õ¡Ç‹Ò áÅм٠Œ»†ÇÂäÁ‹ÁÕÍÒ¡ÒõÑÇàËÅ×ͧ µÒàËÅ×ͧã¹ÃÐËNjҧ¡ÒÃÃÑ¡ÉÒ (à͹¡ ÁØ ‹§ÍŒÍÁ¡ÅÒ§, 2564) ´Ñ§¹Ñ é¹ ÂÒ¿‡Ò·ÐÅÒÂâ¨Ã¨Ö§¹‹Ò¨Ð໚¹¤ÇÒÁËÇѧÍÕ¡·Ò§Ë¹Öè§ÊíÒËÃѺǧ¡ÒÃᾷ 㹡ÒÃÈÖ¡ÉÒÃÐÂÐÂÒǵ‹Íä»